|
[1]
|
Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs:successes, challenges and opportunities[J]. Mol Oncol, 2012, 6 (2):155-176. |
|
[2]
|
Kalyaanamoorthy S, Phoebe Chen Y-P. Structure-based drug design to augment hit discovery[J]. Drug Discov Today, 2011, 16(17-18):831-839. |
|
[3]
|
Kutchukian PS, Shakhnovich EI. De novo design:balancing novelty and confined chemical space[J]. Expert Opin Drug Discov, 2010. 5(8), 789-812. |
|
[4]
|
Park H, Jeong Y, Hong S. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors[J]. Bioorg Med Chem Lett, 2012, 22(2):1027-1030. |
|
[5]
|
Schneider G, Fechner U. Computer-based de novo design of drug-like molecules[J]. Nat Rev Drug Discov 2005, 4 (8):694-663. |
|
[6]
|
Lipinski,C, Hopkins A. Navigating chemical space for biology and medicine[J]. Nature, 2004,432(7019):855-861. |
|
[7]
|
Platania CB, Salomone S, Leggio GM, et al. Homology modeling of dopamine d(2) and d(3) receptors:molecular dynamics refinement and docking evaluation[J]. PloS One, 2012, 7 (9):44316. |
|
[8]
|
Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches[J]. Drug Discov Today, 2006, 11(15-16), 741-748. |
|
[9]
|
Bohm HJ. The computer program LUDI:a new method for de novo design of enzyme inhibitors[J]. J Comput Aided Mol Des, 1992, 6 (1):61-78. |
|
[10]
|
Wang RX, Gao Y, Lai LH. LigBuilder:a multi-purpose progrom for structure-based drug design[J]. J Mol Model, 2000, 6 (7-8); 498-516. |
|
[11]
|
Wang RX, Liu L, Lai LH, et al. SCORE:A new empirical method for estimating the binding affinity of a protein-ligand complex[J]. J Mol Model, 1998, 4 (12):370-394. |
|
[12]
|
Yuan,YX, Pei JF, Lai LH. LigBuilder 2:a practical de novo drug design approach[J]. J Chem Inform Model, 2011, 51 (5):1083-1091. |
|
[13]
|
Cramer RD. Design and preliminary results of LeapFrog, a second generation de novo drug discovery tool[J]. J Mol Graphics, 1993, 11(4); 271-272. |
|
[14]
|
Ambure PS, Gangwal RP, Sanganwar AT. 3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors[J]. Mol Divers, 2012,16(2):377-388. |
|
[15]
|
Makhija MT, Kasliwal RT, Kulkarni VM, et al. De novo design and synthesis of HIV-1 integrase inhibitors[J]. Bioorg Med Chem, 2004, 12(9):2317-2333. |
|
[16]
|
Schinerider G, Neidhart W, Giller T, et al. Scaffold-Hopping by topological search:a contribution to virtual screening[J]. Angewandte Chemie (International Ed. in English), Angew Chem Int Ed Engl, 1999, 38(19):2894-2896. |
|
[17]
|
Schneider G. De novo design-hopping against hope[EB/OL]. Drug Discovery Today:Technologies.(2012-06-20)[2013-01-02]. |
|
[18]
|
Wolber G. 3D pharmacophore elucidation and virtual screening[J]. Drug Discov Today, 2010, 7(4):203-204. |
|
[19]
|
Lauri G, Bartlett PA. CAVEAT:a program to facilitate the design of organic molecules[J]. J Comput Aided Mol Des, 1994, 8(1):51-66. |
|
[20]
|
Beno BR, Langley DR. MORPH:a new tool for ligand design[J]. J Chem Inform Model, 2010, 50(6):1159-1164. |
|
[21]
|
Maass P, Schulz-Gasch T, Stahl M, et al. Recore:a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations[J]. J Chem Inform Model, 2007,47(2):390-399. |
|
[22]
|
Gillet VJ, Newell W, Mata P, et al. SPROUT:recent developments in the de novo design of molecules[J]. J Chem Inform Comput Sci, 1994, 34:207-217. |
|
[23]
|
Vinkers HM, de Jonge MR, Daeyaert FF, et al. SYNOPSIS:SYNthesize and optimize system in silico[J]. J Med Chem, 2003, 46:2765-2773. |
|
[24]
|
Pierce AC, Rao G, Bemis GW, et al. BREED generating novel inhibitors through hybridization of known ligands. Aplication to CDK2, p38and HIV protease[J]. J Med Chem, 2004, 47:2768-2775. |
|
[25]
|
Marra E, Palombo F, Ciliberto G, et al. Intratumoral electro-transfer of small interfering RNA against kinesin spindle protein (KSP) slows down tumor progression[J]. J Cell Physiol, 2013,228(1),58-64. |
|
[26]
|
Jiang,C, Yang L, Wu WT, et al. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors[J]. Bioorg Med Chem, 2011,19 (18):5612-5627. |
|
[27]
|
Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis[J]. Am J Pathol, 2012, 181(2):376-379. |
|
[28]
|
Uno M, Ban HS, Nabeyama W, et al. De novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors[J]. Org Biomol Chem, 2008, 6 (6):979-981. |
|
[29]
|
Albert H, Santos S, Battaqlia E, et al. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells[J]. Clin Chem Lab Med, 2011, 49(10):1707-1714. |
|
[30]
|
Park H, Bahn YJ, Ryu SE, Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(15):4330-4334. |
|
[31]
|
Zhou DJ, Mei Q, Li JT, et al, Cyclophilin A and viral infections[J]. Bioch Biophys Res Comm, 2012,424(4), 647-650. |
|
[32]
|
Choi KJ, Piao YJ, Lim MJ, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death[J]. Cancer Res, 2007, 67(8):3654-3662. |
|
[33]
|
Ni SS, Yuan YX, Huang J, et al. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach[J]. J Med Chem, 2009, 52(17):5295-5298. |
|
[34]
|
Wong C, Chen S. The development,application and limitations of breast cancer cell lines to study tamoxifen and aromataes inhibitor resistance[J]. J Steroid Biochem Mol Biol, 2012, 131(3-5):83-92. |
|
[35]
|
Gueto C, Torres J, Vivas-Reyes R. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators[J]. Eur J Med Chem, 2009, 44(9):3445-3451. |
|
[36]
|
Su B, Diaz-Cruz ES, Landini S, et al. Novel sulfonanilide analoguew suppress aromataes expression and activity in breast cancer cells independent of COX-2 inhibiton[J]. J Med Chem, 2006, 49(4):1413-1419. |
|
[37]
|
Davies H, Bignell GR, Cox C, et al. Mutations of the B-raf gene in human cancer[J]. Nature, 2002, 417(6892), 949-954. |
|
[38]
|
Gopalsamy A, Shi M, Hu Y, et al. B-raf kinase inhibitors:hit enrichment through scaffold hopping[J]. Bioorg Med Chem Lett, 2010, 20(8):2431-2434. |
点击查看大图
下载:
